Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.72 |
| ▸ | EDNRB | P24530 | 13/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | DHPS | P49366 | 1/20 | 0.72 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.72 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770411 | 1.00 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL625550 | 0.99 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5686011 | 0.99 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL3232307 | 0.94 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL13430582 | 0.94 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1938981 | 0.93 | EDNRA (0.78) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7293756 | 0.92 | EDNRA (0.62) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7305726 | 0.91 | EDNRA (0.63) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1259727 | 0.90 | EDNRA (0.69) | EDNRAEDNRB | |
| SCHEMBL7694756 | 0.90 | EDNRA (0.59) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907275-A | Preparation method of bosentan | 武汉工程大学 | 2022-08-16 | — | — | CN | claimed |
| EP-2621909-B1 | PROCESS FOR PREPARING BOSENTAN MONOHYDRATE AND ITS INTERMEDIATES | ZACH SYSTEM SPA (IT) | 2018-12-19 | — | — | EP | claimed |
| EP-2406235-B1 | PROCESS FOR THE PREPARATION OF BOSENTAN | SIFAVITOR S R L (IT) | 2016-08-10 | — | — | EP | claimed |
| US-9233936-B2 | Process for the preparation of bosentan | SIFAVITOR S.R.L. (IT) | 2016-01-12 | — | — | US | claimed |
| WO-2014104904-A1 | PROCESS FOR PREPARATION OF BOSENTAN MONOHYDRATE OF PHARMACEUTICAL PURITY | INSTYTUT FARMACEUTYCZNY (PL) | 2014-07-03 | — | — | WO | claimed |
| US-8664390-B2 | Process for the introduction of hydroxyethoxy side chain in bosentan | GENERICS (UK) LIMITED (GB) | 2014-03-04 | — | — | US | claimed |
| WO-2013186706-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | CADILA PHARMACEUTICALS LTD (IN) | 2013-12-19 | — | — | WO | claimed |
| US-8481730-B2 | Method of synthesis of Bosentan, its polymorphic forms and its salts | CIPLA LIMITED (IN) | 2013-07-09 | — | — | US | claimed |
| US-20120041200-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | SIFAVITOR S.R.L. (IT) | 2012-02-16 | — | — | US | claimed |
| WO-2011021216-A2 | IMPROVED PROCESS FOR THE PREPARATION OF 4-(1,1-DIMETHYLETHYL)-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)[2,2'-BIPYRIMIDIN]-4-YL]BENZENESULFONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| EP-2240469-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | Actavis Group PTC EHF (IS) | 2010-10-20 | — | — | EP | claimed |
| EP-2238118-A1 | METHOD OF SYNTHESIS OF BOSENTAN, ITS POLYMORPHIC FORMS AND ITS SALTS | Cipla Limited (IN) | 2010-10-13 | — | — | EP | claimed |
| US-20100249162-A1 | PROCESS FOR THE INTRODUCTION OF HYDROXYETHOXY SIDE CHAIN IN BOSENTAN | GENERICS [UK] LIMITED | 2010-09-30 | — | — | US | claimed |
| EP-2170841-A1 | PROCESS FOR INTRODUCTION OF HYDROXYETHOXY SIDE CHAIN IN BOSENTAN | Merck Generics (UK) Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| WO-2009093127-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-07-30 | — | — | WO | claimed |
| WO-2009083739-A1 | METHOD OF SYNTHESIS OF BOSENTAN, ITS POLYMORPHIC FORMS AND ITS SALTS | CIPLA LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2009004374-A1 | PROCESS FOR INTRODUCTION OF HYDROXYETHOXY SIDE CHAIN IN BOSENTAN | GENERICS [UK] LIMITED (GB) | 2009-01-08 | — | — | WO | claimed |
| US-6720322-B2 | USE AS ENDOTHELIN RECEPTOR ANTAGONISTS. | ACTELION PHARAMCEUTICALS LTD. (CH) | 2004-04-13 | — | — | US | claimed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249162-A1 | PROCESS FOR THE INTRODUCTION OF HYDROXYETHOXY SIDE CHAIN IN BOSENTAN | EDNRB, EDNRA, ECE2 | EDNRA 2/4885EDNRB 1/4885ABCC3 2405/4885 |
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | EDNRA 3/4885EDNRB 2/4885ABCC3 1351/4885 |
| US-20120041200-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | EDNRB, BDKRB2, EDNRA | EDNRA 3/4885EDNRB 1/4885ABCC3 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.